Myelofibrosis News and Research

RSS

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Study finds two drugs capable of slowing bone marrow cancer progression

Primary myelofibrosis (PMF), a relatively rare but painful type of bone marrow cancer, disrupts the body's normal production of blood cells by causing extensive scarring in the bone marrow.

22 Mar 2021

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

26 Jan 2021

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Novel super-activating macrophage receptor could explain hyper-inflammation in severe COVID-19

Immunity is a curious thing. While essential in protecting the body against invading pathogens and foreign antigens, it can also turn against the body and trigger destructive immunological processes. A new study published on the preprint server bioRxiv* in November 2020 reports on the role played by hyperactive macrophages in a range of acute and chronic hyper-inflammatory conditions.

10 Nov 2020

Beta-blockers could be used to treat COVID-19, study finds

Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists.

3 Nov 2020

SARS-CoV-2 infection of carotid arteries may explain vascular involvement in COVID-19

A new study published on the preprint server bioRxiv in October 2020 shows that the virus causing COVID-19, namely, SARS-CoV-2, produces replicative infection in the carotid arteries and affects the vascular responses. This could have a profound bearing on the understanding of the disease and its clinical treatment.

14 Oct 2020

Study takes new treatment approach for blood cancer

In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model.

21 Jun 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Popular cancer drug linked to weight gain and increased systolic blood pressure

FDA approves new drug to treat patients with myelofibrosis

Today, the U.S. Food and Drug Administration approved Inrebic (fedratinib) capsules to treat adult patients with certain types of myelofibrosis.

18 Aug 2019

Research findings lead to new clinical trial for people with myelofibrosis

Researchers at Huntsman Cancer Institute at the University of Utah (U of U) discovered in laboratory studies that an experimental drug called selinexor may block a crucial survival pathway exploited by myelofibrosis cells.

20 Jun 2019

Bone marrow disease is stimulated by vitamin D and immune cells, reveals research

The bone marrow disease myelofibrosis is stimulated by excessive signaling from vitamin D and immune cells known as macrophages, reveals a Japanese research team. These findings could help to develop alternative treatments that do not target problem genes.

11 Feb 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

Newly developed molecules may provide more reliable relief for people with autoimmune diseases

Living with an autoimmune disease can feel like an insider is attacking your body. An estimated 24 million people in the United States are affected by autoimmune diseases, a group of diseases in which a person's immune system attacks part of the person's own body.

7 Dec 2018

Researchers find STAT3 as therapeutic target for chronic active EBV infection

Tokyo Medical and Dental University study shows that ruxolitinib-induced inhibition of STAT3 activity blocks survival and reduces pro-inflammatory cytokine production in Epstein-Barr virus (EBV)-infected clonally proliferating T- or NK-cells in Chronic active Epstein-Barr virus infection.

20 Aug 2018

Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow

Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life enhanced.

18 Jun 2018

Detailed structure of protein pair offers blueprint for new medicines

Walter and Eliza Hall Institute researchers have visualized for the first time how the protein SOCS1 'switches off' cell signaling to dampen immune responses and block cancer growth.

4 Jun 2018

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

New genetic model identified for predicting outcomes in patients with primary myelofibrosis

A group of investigators from Mayo Clinic and multiple academic research centers in Italy have identified a genetic model for predicting outcomes in patients with primary myelofibrosis who are 70 years or younger and candidates for stem cell transplant to treat their disease.

11 Dec 2017